Skip to main content
SpringerLink
Log in

Novel Drug Delivery Systems for Antifungal Agents

  • Chapter
Human Fungal Pathogens

Part of the book series: The Mycota ((MYCOTA,volume 12))

Abstract

Invasive fungal infections have continued to expand in recent years due to increasing populations of patients at high risk because of their immunocompromised conditions such as cancer, bone marrow or solid-organ transplantation, HIV infection, or chronic corticosteroid administration (Fisher-Hoch and Hutwagner 1995; Fridkin and Jarvis 1996). With this increase in severe systemic fungal infections, there has been a heightened need to develop new, more potent antifungal agents to treat these life-threatening fungal diseases. Some of the agents that have been developed for this purpose are toxic to the host. Others have only been administered orally since they are too difficult to solubilize for parenteral administration. These factors have limited the clinical use of some drugs and have spurred research in the development of novel drug delivery systems to improve antifungal drug efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 309.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 399.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122–1128

    Article  PubMed  CAS  Google Scholar 

  • Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA (1997) Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 41:2201–2208

    PubMed  CAS  Google Scholar 

  • Adler-Moore JP (1994) AmBisome targeting to fungal infections. Bone Marrow Transplant 14(suppl 5):S3–S7

    PubMed  Google Scholar 

  • Adler-Moore JP, Proffitt RT (1993) Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Lip Res 3:429–450

    Article  CAS  Google Scholar 

  • Adler-Moore JP, Proffitt RT (1998) AmBisome: long circulating formulation of amphotericin B. In: Woodle MC, Storm G (eds) Long circulating liposomes: old drugs, new therapeutics. Springer, Berlin Heidelberg New York, pp 185–206

    Chapter  Google Scholar 

  • Adler-Moore J, Proffitt RT (2002) AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J Antimicrob Chemother 2002 Jan,49 (Suppl A):21–30

    Article  CAS  Google Scholar 

  • Albert MM, Stahl-Carroll L, Luther MF, Graybill JR (1995) Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 5:1–6

    Google Scholar 

  • Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffitt RT (1994) Prophylactic efficacy of aerolized liposomal (AmBisome) and non liposomal (amphotericin B deoxycholate) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 34:1001–1013

    Article  PubMed  CAS  Google Scholar 

  • Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H, Berenguer J, Lyman CA, Pizzo PA, Walsh TJ (1994) Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 38:518–522

    Article  PubMed  CAS  Google Scholar 

  • Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ; Esophageal Candidiasis Study Group (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447–1454

    Article  PubMed  CAS  Google Scholar 

  • Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD (1995) Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 39:2042–2047

    Article  PubMed  CAS  Google Scholar 

  • Anaissie E, Paetznik V, Proffitt R, Adler-Moore J, Bodey GP (1991) Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microb Infect Dis 10:665–668

    Article  CAS  Google Scholar 

  • Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L (1998a) Enhanced bioavailability of itraconazole in hydroxypropylbeta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 42:1862–1865

    PubMed  CAS  Google Scholar 

  • Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L (1998b) Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 18:295–301

    PubMed  CAS  Google Scholar 

  • Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ (1999) Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 16:1694–1701

    Article  PubMed  CAS  Google Scholar 

  • Bennett, JE 1994. Antifungal agents. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 8th edn. McGraw-Hill, New York, pp 1165–1181

    Google Scholar 

  • Bhamra R, Sa’ad A, Bolcsak LE, Janoff AS, Swenson CE (1997) Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob Agents Chemother 41:886–892

    PubMed  CAS  Google Scholar 

  • Bonner DP, Tewari RP, Solotorovsky M, Mechlinski W, Schaffner CP (1975) Comparative chemotherapeutic activity of amphotericin B and amphotericin B methyl ester. Antimicrob Agents Chemother 7:724–729

    Article  PubMed  CAS  Google Scholar 

  • Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K (2001a) Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 45:981–985

    Article  PubMed  CAS  Google Scholar 

  • Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K, Itraconazole Neutropenia Study Group (2001b) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 135:412–422

    Article  PubMed  CAS  Google Scholar 

  • Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ (1998) Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother 42:263–268

    PubMed  CAS  Google Scholar 

  • Boutati HC, Malteau G, Lopez-Berestein G, Vartivarian SE, Anaissie E (1995) 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995, Abstract LM22, p 330

    Google Scholar 

  • Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA (1996) Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 173:1208–1215

    Article  PubMed  CAS  Google Scholar 

  • Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Entezam F, Guy H (1994) A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 33:603–613

    Article  PubMed  CAS  Google Scholar 

  • Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33: e83–90

    Article  PubMed  CAS  Google Scholar 

  • Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D’Athis M, Portier H (1992) Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 305:921–925

    Article  CAS  Google Scholar 

  • Chen WC, Chou DL, Feingold DS (1978) Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob Agents Chemother 13:914–917

    Article  PubMed  CAS  Google Scholar 

  • Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35: 615–621

    Article  PubMed  CAS  Google Scholar 

  • Clemons KV, Stevens DA (1991a) Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 35:1829–1833

    Article  PubMed  CAS  Google Scholar 

  • Clemons KV, Stevens DA (1991b) Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 35:2144–2146

    Article  PubMed  CAS  Google Scholar 

  • Clemons KV, Stevens DA (1993a) Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother 32:465–472

    Article  PubMed  CAS  Google Scholar 

  • Clemons KV, Stevens DA (1993b) Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Amphotericin B deoxycholate) for the treatment of murine paracoccidioidomycosis. J Med Vet Mycol 31:387–394

    Article  Google Scholar 

  • Clemons KV, Stevens DA (1998) Comparison of Amphotericin B deoxycholate, Amphotec, AmBisome and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 42:899–902

    PubMed  CAS  Google Scholar 

  • Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA (2002) Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 46:2420–2426

    Article  PubMed  CAS  Google Scholar 

  • Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JRW (1993) Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7:829–835

    Article  PubMed  CAS  Google Scholar 

  • Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA (1994) NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144

    Article  PubMed  CAS  Google Scholar 

  • Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  PubMed  CAS  Google Scholar 

  • Dismukes WE, Bradsher RW Jr, Cloud GC, Kauffman CA, Chapman SW, George RB, Stevens DA, Girard WM, Saag MS, Bowles-Patton C (1992) Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 93:489–497

    Article  PubMed  CAS  Google Scholar 

  • Ellis WG, Sobel RA, Nielsen SL (1982) Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis 146:125–137

    Article  PubMed  CAS  Google Scholar 

  • Falk R, Domb AJ, Polacheck I (1999) A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob Agents Chemother 43:1975–1981

    PubMed  CAS  Google Scholar 

  • Fielding RM, Smith PC, Wang LH, Porter J, Guo LS (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208–1213

    Article  PubMed  CAS  Google Scholar 

  • Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS (1992) Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 36:299–307

    Article  PubMed  CAS  Google Scholar 

  • Fisher EW, Toma A, Fisher PH, Cheesman AD (1991) Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol 105:575–577

    Article  PubMed  CAS  Google Scholar 

  • Fisher-Hoch SP, Hutwagner L (1995) Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 21:897–904

    Article  PubMed  CAS  Google Scholar 

  • Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ (1994) Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infect. J Infect Dis 169:356–368

    Article  PubMed  CAS  Google Scholar 

  • Fridkin SK, Jarvis WR (1996) Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 9:499–511

    PubMed  CAS  Google Scholar 

  • Garcia A, Adler-Moore JP, Proffitt RT (2000) Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother 44:2327–2332

    Article  PubMed  CAS  Google Scholar 

  • George D, Miniter P, Andriole VT (1996) Efficacy of UK109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40:86–91

    PubMed  CAS  Google Scholar 

  • Goodman JS, Koenig MG (1970) Amphotericin B — specifics of administration. Mod Treatment 7:581–595

    CAS  Google Scholar 

  • Graybill JR, Bocanegra R (1995) Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother 39:1885–1887

    Article  PubMed  CAS  Google Scholar 

  • Groll AH, Gonzalez CE, Giri N, Kligys K, Love W, Peter J, Feuerstein E, Bacher J, Piscitelli SC, Walsh TJ (1999) Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother 43:95–103

    Article  PubMed  CAS  Google Scholar 

  • Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 182:274–282

    Article  PubMed  CAS  Google Scholar 

  • Guo LSS, Fielding RM, Lasic DD (1991) Novel antifungal drug delivery: stable amphotericin B cholesteryl sulfate discs. Int J Pharmaceut 75:45–54

    Article  CAS  Google Scholar 

  • Hamill RJ, Sobel J, El-Sadr W, Johnson P, Graybill JR, Javaly K, Barker D (1999) Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract 1161, pp 490–491

    Google Scholar 

  • Hamilton-Miller JM (1973) Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 37:166–196

    CAS  Google Scholar 

  • Hanson LH, Stevens DA (1992) Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 36:486–488

    Article  PubMed  CAS  Google Scholar 

  • Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310–1313

    Article  PubMed  CAS  Google Scholar 

  • Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, and Katsu K (1996a) In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40:2237–2242

    PubMed  CAS  Google Scholar 

  • Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K (1996b) Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 40:2243–2247

    PubMed  CAS  Google Scholar 

  • Hazen EL, Brown R (1950) Two antifungal agents produced by a soil actinomycete. Science 112:423

    PubMed  CAS  Google Scholar 

  • Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M (1998) Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12: 2227–2228

    PubMed  CAS  Google Scholar 

  • Heinemann V, Bosse D, Jehn U, Kahny B, Wachholz K, Debus A, Scholz P, Kolb HJ, Wilmanns W (1997) Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 41:1275–1280

    PubMed  CAS  Google Scholar 

  • Herbrecht R (1997) Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 16:74–80

    Article  PubMed  CAS  Google Scholar 

  • Hoeprich PD, Huston AC, Wolfe BM (1985) Toxicity of amphotericins on chronic administration to mongrel dogs. Diagn Microbiol Infect Dis 3:47–58

    Article  PubMed  CAS  Google Scholar 

  • Hossain MA, Maesaki S, Kakeya H, Noda T, Yanagihara K, Sasaki E, Hirakata Y, Tomono K, Tashiro T, Kohno S (1998) Efficacy of NS-718, a novel lipid nanosphereencapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob Agents Chemother 42:1722–1725

    PubMed  CAS  Google Scholar 

  • Hossain MA, Maesaki S, Razzaque MS, Tomono K, Taguchi T, Kohno S (2000) Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B. J Antimicrob Chemother 46:263–268

    Article  PubMed  CAS  Google Scholar 

  • Jabado N, Casanova JL, Haddad E, Dulieu F, Fournet JC, Dupont B, Fischer A, Hennequin C, Blanche S (1998) Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 27:1437–1441

    Article  PubMed  CAS  Google Scholar 

  • Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, Taraschi T, Gruner SM, Shyamsunder E, Tate MW, Mendelsohn R, Bonner D (1988) Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 85:6122–6126

    Article  PubMed  CAS  Google Scholar 

  • Janoff AS, Perkins WR, Saletan SL, Swenson CE (1993) Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 3:451–471

    Article  CAS  Google Scholar 

  • Jensen GM, Skenes CR, Bunch TH, Weissman CA, Amirghahari N, Satorius A, Moynihan K, Eley CGS (1999) Determination of the relative toxicity of amphotericin B formulations: A red blood cell potassium release assay. Drug Delivery 6:81–88

    Article  CAS  Google Scholar 

  • Jezequel SG, Clark M, Cole S, Evans KE, Wastall P (1995) UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: preclinical pharmacokinetics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr F76, p 126

    Google Scholar 

  • Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW (1998) Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 42:1412–1416

    PubMed  CAS  Google Scholar 

  • Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE (2002) Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137: 105–109

    Article  PubMed  CAS  Google Scholar 

  • Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, Sherman JW (1991) Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 164: 418–421

    Article  PubMed  CAS  Google Scholar 

  • Keim GR Jr, Sibley PL, Yoon YH, Kulesza JS, Zaidi IH, Miller MM, Poutsiaka JW (1976) Comparative toxicological studies of amphotericin B methyl ester and amphotericin B in mice, rats, and dogs. Antimicrob Agents Chemother 10:687–690

    Article  PubMed  CAS  Google Scholar 

  • Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, Mufti GJ (1999) Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23:163–168

    Article  PubMed  CAS  Google Scholar 

  • Kinsky SC (1961) Alterations in the permeability of Neurospora crassa due to polyene antibiotics. J Bacteriol 82:889–897

    PubMed  CAS  Google Scholar 

  • Koltin Y, Hitchcock CA (1997) The search for new triazole antifungal agents. Curr Opin Chem Biol 1:176–182

    Article  PubMed  CAS  Google Scholar 

  • Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42:395–402

    PubMed  CAS  Google Scholar 

  • Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713–718

    Article  PubMed  CAS  Google Scholar 

  • Leenders ACAP, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA (1996) Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 38:215–225

    Article  PubMed  CAS  Google Scholar 

  • Leenders ACAP, Reiss P, Portegies P, Clezy K, Hop WCJ, Hoy J, Borleffs JCC, Allworth T, Kauffmann RH, Jones P, Kroon FP, Verbrugh HA, de Marie S (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11:1463–1471

    Article  PubMed  CAS  Google Scholar 

  • Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, Verbrugh HA, de Marie S (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205–212

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano R (1983) Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 147:939–945

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano R, Bodey GP (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 51:704–710

    Article  Google Scholar 

  • Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K (1987) Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 5:310–317

    PubMed  CAS  Google Scholar 

  • Louria DB (1958) Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiot Med 5:295–301

    PubMed  CAS  Google Scholar 

  • Luke RG, Boyle JA (1998) Renal effects of amphotericin B lipid complex. Am J Kidney Dis 31:780–785

    Article  PubMed  CAS  Google Scholar 

  • Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE (1997) Infection due to fluconazoleresistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 24:28–34

    Article  PubMed  CAS  Google Scholar 

  • Marichal P, Gorrens J, Vanden Bossche H (1985) The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger. Sabouraudia 23:13–21

    Article  PubMed  CAS  Google Scholar 

  • McAndrews BJ, Lee MJA, Adler-Moore JP (1993) Comparative toxicities of amphotericin B deoxycholate and AmBisome for cultured kidney cells and macrophages. General Proceedings of the ASM Meeting for American Society for Microbiology, Atlanta, Georgia, Abst A-57, p 11

    Google Scholar 

  • McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG (1998) In vitro activity of voriconazole against selected fungi. Med Mycol 36:239–242

    PubMed  CAS  Google Scholar 

  • Mechlinski W, Schaffner CP (1972) Polyene macrolide derivatives. I. N-acylation and esterification reactions with amphotericin B. J Antibiot (Tokyo) 25:256–258

    Article  CAS  Google Scholar 

  • Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G (1987a) Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 31:1897–1900

    Article  PubMed  CAS  Google Scholar 

  • Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G (1987b) Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 31:1901–1903

    Article  PubMed  CAS  Google Scholar 

  • Moore CB, Walls CM, Denning DW (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 44:441–443

    Article  PubMed  CAS  Google Scholar 

  • Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E (2000) Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 31:1499–1501

    Article  PubMed  CAS  Google Scholar 

  • Nguyen MH, Yu CY (1998) Voriconazole against fluconazole-susceptible and resistant Candida isolates: invitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 42:253–256

    Article  PubMed  CAS  Google Scholar 

  • Nomeir AA, Kumari P, Hilbert MJ, Gupta S, Loebenberg D, Cacciapuoti A, Hare R, Miller GH, Lin CC, Cayen MN (2000) Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 44:727–731

    Article  PubMed  CAS  Google Scholar 

  • Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ (1998) Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 26:461–467

    Article  PubMed  CAS  Google Scholar 

  • Oakley KL, Moore CB, Denning DW (1999) Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 43:1264–1266

    PubMed  CAS  Google Scholar 

  • Odds FC, Vanden Bossche HV (2000) Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 45:371–373

    Article  PubMed  CAS  Google Scholar 

  • Olson JA, Proffitt RT, Adler-Moore JP (2002) Post-antibiotic effect of high dose AmBisome (AmBis) three weeks after treatment. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, Abstr P1353, p 316

    Google Scholar 

  • Ortoneda M, Pastor FJ, Pujol I, Guarro J (2001) Successful treatment of murine fusariosis with high doses of liposomal amphotericin B. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, Abst J-1830, p 396

    Google Scholar 

  • Otsubo T, Maesaki S, Hossain MA, Yamamoto Y, Tomono K, Tashiro T, Seki J, Tomii Y, Sonoke S, Kohno S (1999) In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob Agents Chemother 43:471–475

    PubMed  CAS  Google Scholar 

  • Otsubo T, Maruyama K, Maesaki S, Miyazaki Y, Tanaka E, Takizawa T, Moribe K, Tomono K, Tashiro T, Kohno S (1998) Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 42:40–44

    PubMed  CAS  Google Scholar 

  • Patterson BE, Coates PE (1995) UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr, F78, p 126

    Google Scholar 

  • Perfect JR, Wright KA (1994) Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 33:73–81

    Article  PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46:1032–1037

    Article  PubMed  CAS  Google Scholar 

  • Prentice HG, Hann IM, Hebrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711–718

    Article  PubMed  CAS  Google Scholar 

  • Proffitt RT, Satorius A, Chiang S-M, Sullivan L, Adler-Moore JP (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 28 (suppl B):49–61

    Article  PubMed  CAS  Google Scholar 

  • Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553

    Article  PubMed  CAS  Google Scholar 

  • Radford SA, Johnson EM, Warnock DW (1997) In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41:841–843

    PubMed  CAS  Google Scholar 

  • Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson DO (1995) Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 84: 927–932

    Article  PubMed  CAS  Google Scholar 

  • Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL (1997) Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24:235–247

    Article  PubMed  CAS  Google Scholar 

  • Ruhnke M, Schmidt-Westhausen A, Trautmann M (1997) In vitro activities of voriconazole (UK-109,486) against fluconazole susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41:575–577

    PubMed  CAS  Google Scholar 

  • Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG (1991) Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 35:1029–1034

    Article  PubMed  CAS  Google Scholar 

  • Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24:527–538

    Article  PubMed  CAS  Google Scholar 

  • Seabury JH, Bascomb HE (1960) Experience with amphotericin B. Ann NY Acad Sci 89:202–220

    Article  PubMed  CAS  Google Scholar 

  • Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC Jr, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22:315–321

    Article  PubMed  CAS  Google Scholar 

  • Sievers TM, Kubak BM, Wong-Beringer A (1996) Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 38:333–347

    Article  PubMed  CAS  Google Scholar 

  • Smith D, van de Velde V, Woestenborghs R, Gazzard BG (1992) The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 44:618–619

    Article  PubMed  CAS  Google Scholar 

  • Sperry PJ, Cua DJ, Wetzel SA, Adler-Moore JP (1998) Antimicrobial activity of AmBisome and nonliposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med Mycol 36:135–141

    Article  PubMed  CAS  Google Scholar 

  • Stevens DA (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy 19:603–611

    Article  PubMed  CAS  Google Scholar 

  • Sugar AM, Liu XP (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40:1314–1316

    PubMed  CAS  Google Scholar 

  • Sugar AM, Liu XP (2001) Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 45:601–604

    Article  PubMed  CAS  Google Scholar 

  • Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC (2000) Amphotericin B colloidal dispersion (Amphocil) vs. fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 25:879–884

    Article  PubMed  CAS  Google Scholar 

  • Tollemar J, Hockerstedt K, Ericzon B-G, Jalanko H, Ringdén O (1995) Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 59:45–50

    Article  PubMed  CAS  Google Scholar 

  • Tomaszewski K, Purkins L (2001) The pharmacokinetics (PK) and safety of sulfobutylether-ß-cyclodextrin (SBECD) 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Abst A-23, p3

    Google Scholar 

  • Vandewoude K, Vogelaers D, Decruyenaere J, Jaqmin P, De Beule K, Van Peer A, Woestenborghs R, Groen K, Colardyn F (1997) Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41:2714–2718

    PubMed  CAS  Google Scholar 

  • van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ (1995) Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Amphotericin B deoxycholate) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 35:509–519

    Article  PubMed  Google Scholar 

  • van Etten EW, Snijders SV, van Vianen W, Bakker-Woudenberg IA (1998) Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. Antimicrob Agents Chemother 42:2431–2433

    PubMed  Google Scholar 

  • Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E (1997) Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 41:2238–2243

    PubMed  CAS  Google Scholar 

  • Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W (1998a) Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–2398

    PubMed  CAS  Google Scholar 

  • Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998b) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383–1396

    Article  PubMed  CAS  Google Scholar 

  • Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999a) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340:764–771

    Article  PubMed  CAS  Google Scholar 

  • Walsh TJ, Seibel NL, Arndt C, Harris RE, Dinubile MJ, Reboli A, Hiemenz J, Chanock SJ (1999b) Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18:702–708

    Article  PubMed  CAS  Google Scholar 

  • Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45:3487–3496

    Article  PubMed  CAS  Google Scholar 

  • Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR (2002a) Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21:240–248

    Article  PubMed  Google Scholar 

  • Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J, The National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002b) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    Article  PubMed  CAS  Google Scholar 

  • Wasan KM, Ramaswamy M, Cassidy SM, Kazemi M, Strobel FW, Thies RL (1997) Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother 41: 1871–1875

    PubMed  CAS  Google Scholar 

  • Welch M (2000) Aronex’s Nyotran falls short in phase III vs. Amphotericin B. BioWorld Today II(32):1

    Google Scholar 

  • Wheat LJ, Cloud G, Johnson PC, Connolly P, Goldman M, Le Monte A, Fuller DE, Davis TE, Hafner R (2001) Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 45:2354–2357

    Article  PubMed  CAS  Google Scholar 

  • White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635–642

    PubMed  CAS  Google Scholar 

  • White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27: 296–302

    Article  PubMed  CAS  Google Scholar 

  • Wingard JR. (1997) Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 19:343–347

    Article  PubMed  CAS  Google Scholar 

  • Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163

    Article  PubMed  CAS  Google Scholar 

  • Zhao Q, Zhou H, Pesco-Koplowitz L (2001) Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. J Clin Pharmacol 41:1319–1328

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Sciences, California State Polytechnic University, Pomona, California, 91768, USA

    R. T. Proffitt

Authors
  1. J. P. Adler-Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. T. Proffitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cratis D. Williams Graduate School, Appalachian State University, Boone, North Carolina, 28607, USA

    Judith E. Domer (Dean of Graduate Studies and Research) (Dean of Graduate Studies and Research)

  2. Department of Medicine, Washington University School of Medicine, Box 8051, 660 South Euclid Avenue, St. Louis, Missouri, 63110, USA

    George S. Kobayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adler-Moore, J.P., Proffitt, R.T. (2004). Novel Drug Delivery Systems for Antifungal Agents. In: Domer, J.E., Kobayashi, G.S. (eds) Human Fungal Pathogens. The Mycota, vol 12. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10380-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10380-7_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-07651-0

  • Online ISBN: 978-3-662-10380-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation